The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Novel classification system to improve post-transplant AML prognosis
Antonio Jimenez, MD, Sylvester Comprehensive Cancer Center, Miami Springs, FL, discusses a study aiming to evaluate the prognostic ability of a modified European LeukemiaNet (mELN) classification system based on available Center for International Blood and Marrow Transplant Research (CIBMTR) data, to predict post-transplant outcomes in acute myeloid leukemia (AML) patients. Over two thousand AML patients in their first remission were initially stratified into three groups: favorable (Fav), intermediate (IM), and adverse (Adv). While significant differences were found among the groups in terms of relapse, disease-free survival, and overall survival, the results for the Fav and IM groups were comparable and the stratification was ultimately changed to two groups: favorable and unfavorable. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
